(Total Views: 507)
Posted On: 10/23/2022 4:45:36 PM
Post# of 157747
Let's forget about arbitration...for the moment...after all...it's arbitrary.
Mesdames et messieurs...I direct your attention to the center ring.
Prior to Jan 5th, 2022...a statement by Dr. Christopher Recknor, Sr. Exec. V.P of Clinical Operations...
"We are in the process of analyzing biomarker Data including CCR5 haplotype information to better understand responder rates and MOA...given that 5% of the world's population is estimated to have NASH with 20% progressing to cirrhosis, this signal gives hope for a therapeutic intervention for this disease".
"We believe we have a UNIQUE drug... with tremendous opportunities " _Nader.
Where...Oh where have I heard this before?
Mesdames et messieurs...I direct your attention to the center ring.
Prior to Jan 5th, 2022...a statement by Dr. Christopher Recknor, Sr. Exec. V.P of Clinical Operations...
"We are in the process of analyzing biomarker Data including CCR5 haplotype information to better understand responder rates and MOA...given that 5% of the world's population is estimated to have NASH with 20% progressing to cirrhosis, this signal gives hope for a therapeutic intervention for this disease".
"We believe we have a UNIQUE drug... with tremendous opportunities " _Nader.
Where...Oh where have I heard this before?
(4)
(0)
